MoleculeDx Journal · Patient education

Beyond Ultrasound and AFP: A New Molecular Approach to Liver Cancer Screening

Explore how fusion-transcript blood testing offers a new molecular approach to liver cancer surveillance and how Fusion-detect™ could address limitations of conventional methods.

How Fusion-detect™ uses cancer-associated RNA signals to address limitations of conventional liver cancer surveillance

Why does liver cancer surveillance need better technology?

Hepatocellular carcinoma (HCC), the most common primary liver cancer, can develop without noticeable symptoms. Early detection is particularly important because patients with small, localized tumors may be eligible for potentially curative treatments.

For decades, liver cancer surveillance has relied primarily on ultrasound and alpha-fetoprotein (AFP) blood testing. Although these approaches are widely used, their ability to detect early-stage cancer is limited.

According to the 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance, a meta-analysis estimated that ultrasound alone detected approximately 53% of early-stage HCC, while ultrasound combined with AFP achieved approximately 63% sensitivity.

These limitations demonstrate the need for new surveillance technologies capable of identifying cancer-associated signals that conventional approaches may miss.

Why might fusion-transcript testing offer an advantage?

Ultrasound identifies structural abnormalities in the liver. AFP measures a protein that may increase in some patients with liver cancer.

Fusion-transcript testing takes a different approach. Certain cancer-associated genomic rearrangements produce abnormal RNA fusion transcripts. These molecular signals can be detected in blood samples using sensitive laboratory methods.

Research published in Oncotarget in 2019 demonstrated the detection of selected fusion transcripts in serum samples from patients with HCC. A subsequent study published in the American Journal of Pathology in 2024 evaluated fusion-transcript combinations and machine-learning models for predicting HCC.

Together, these studies established an important scientific foundation for blood-based fusion-transcript analysis.

Fusion-detect™: A proprietary molecular surveillance approach

MoleculeDx developed Fusion-detect™ to evaluate cancer-associated fusion-transcript signals in blood.

Its Liver Cancer Fusion Predictor uses a proprietary multivariable approach to identify molecular patterns associated with HCC.

In clinical validation reported by MoleculeDx, Fusion-detect™ demonstrated:

96.7% overall accuracy

94.2% sensitivity

98.1% specificity

These internally reported validation figures demonstrate the potential of the approach in the evaluated population. They are not a direct head-to-head comparison with ultrasound-plus-AFP surveillance and do not establish superiority in a prospective surveillance population.

Unlike conventional imaging-based surveillance, Fusion-detect™ evaluates molecular signals rather than relying on visualization of a liver lesion.

This distinction creates an opportunity to develop a new generation of liver cancer surveillance.

Could molecular testing replace conventional surveillance?

MoleculeDx is pursuing a proposed surveillance strategy in which the Liver Cancer Fusion Predictor could replace conventional ultrasound-plus-AFP screening, either as a stand-alone molecular surveillance test or in combination with ultrasound.

This represents a potential shift from primarily imaging- and protein-based surveillance toward molecular analysis of cancer-associated RNA.

The proposed replacement indication has not yet been authorized by the FDA. Until such use is authorized and incorporated into clinical recommendations, patients should follow their healthcare professionals' existing surveillance plans.

A positive molecular surveillance result requires appropriate clinical evaluation and does not independently establish a diagnosis of liver cancer.

The future of liver cancer surveillance

The development of blood-based fusion-transcript testing introduces a different strategy for identifying possible HCC.

Rather than relying exclusively on tumor visualization and AFP concentrations, molecular surveillance examines cancer-associated signals detectable in blood.

Fusion-detect™ represents MoleculeDx's effort to translate that scientific approach into clinical surveillance, with the goal of improving early liver cancer detection.

Medical information disclaimer: This article provides general educational information and does not replace individualized medical advice or diagnostic evaluation.

References

Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–1965. doi:10.1097/HEP.0000000000000466.

Yu YP, et al. Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma. Oncotarget. 2019;10:3352–3360. doi:10.18632/oncotarget.26918.

Yu YP, Liu S, Geller DA, Luo JH. Serum fusion transcripts to assess the risk of hepatocellular carcinoma and the impact of cancer treatment through machine learning. American Journal of Pathology. 2024;194:1262–1271. doi:10.1016/j.ajpath.2024.02.017.

← Back to the Journal

Educational information only; consult a qualified healthcare professional. Screening does not establish or exclude a diagnosis.